ENTREMED AND THE NATIONAL CANCER INSTITUTE COMMENCE RESEARCH COLLABORATION

EntreMed, Inc. (Nasdaq: ENMD - News), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to evaluate the role of HIF-1alpha inhibition in the treatment of cancer.

Yahoo News (http://biz.yahoo.com/prnews/050915/dcth006.html?.v=27)